Boothbay Fund Management’s Cytokinetics CYTK Stock Holding History

Boothbay Fund Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$9.99M	Buy	151,600 +68,900	+83%	+$4.38M	0.13%	134
2025 Q4	$5.25M	Buy	82,700 +39,100	+90%	+$2.43M	0.08%	277
2025 Q3	$2.4M	Sell	43,600 -10,000	-19%	-$412K	0.03%	523
2025 Q2	$1.77M	Buy	+53,600	New	+$1.86M	0.03%	529
2024 Q4	–	Sell	-15,300	Closed	-$808K	–	1582
2024 Q3	$808K	Buy	+15,300	New	+$853K	0.02%	815
2024 Q1	–	Sell	-192,000	Closed	-$16M	–	1641
2023 Q4	$16M	Buy	192,000 +150,600	+364%	+$5.45M	0.41%	24
2023 Q3	$1.22M	Buy	+41,400	New	+$1.38M	0.03%	676
2022 Q4	–	Sell	-104,400	Closed	-$5.06M	–	2080
2022 Q3	$5.06M	Buy	+104,400	New	+$5.02M	0.13%	189
2021 Q1	–	Sell	-169	Closed	-$351K	–	1588
2020 Q4	$351K	Sell	169 -1,102	-87%	-$20.1K	0.01%	891
2020 Q3	$2.75M	Buy	+1,271	New	+$29.7K	0.17%	146
2020 Q2	–	Sell	-577	Closed	-$680K	–	998
2020 Q1	$680K	Buy	+577	New	+$7.36K	0.06%	390

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Boothbay Fund Management's CYTK Position: Q1 2026 in Review

Boothbay Fund Management increased its Cytokinetics (CYTK) stake by 85% in Q1 2026, buying an estimated $3.05M and bringing the position to 104,445 shares worth $6.88M. The position accounts for 0.09% of the portfolio, ranked #227.

Boothbay Fund Management first reported a position in CYTK in Q2 2018 and has held it in 17 quarters since. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

Boothbay Fund Management held 104,445 shares of Cytokinetics worth $6.88M as of Q1 2026.
Boothbay Fund Management bought 47,992 Cytokinetics shares in Q1 2026, an estimated $3.05M.
Cytokinetics made up 0.09% of Boothbay Fund Management's portfolio in Q1 2026, its #227 holding.
Boothbay Fund Management first reported a position in Cytokinetics in Q2 2018 and has held it in 17 quarters since.
439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.